165 related articles for article (PubMed ID: 36788084)
21. HER2-positive endometrial cancer subtype carries poor prognosis.
Lapińska-Szumczyk S; Supernat A; Majewska H; Gulczyński J; Luczak A; Biernat W; Wydra D; Zaczek AJ
Clin Transl Sci; 2014 Dec; 7(6):482-8. PubMed ID: 25201050
[TBL] [Abstract][Full Text] [Related]
22. TCGA molecular subgroups of endometrial carcinoma in ovarian endometrioid carcinoma: A quantitative systematic review.
D'Alessandris N; Travaglino A; Santoro A; Arciuolo D; Scaglione G; Raffone A; Inzani F; Zannoni GF
Gynecol Oncol; 2021 Nov; 163(2):427-432. PubMed ID: 34446267
[TBL] [Abstract][Full Text] [Related]
23. Mesonephric-like Endometrial Carcinoma: Results From Immunohistochemical Screening of 300 Endometrial Carcinomas and Carcinosarcomas for This Often Overlooked and Potentially Aggressive Entity.
Mills AM; Jenkins TM; Howitt BE; Fan J; Ring KL; Cook I
Am J Surg Pathol; 2022 Jul; 46(7):921-932. PubMed ID: 35195579
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathological and molecular characterisation of 'multiple-classifier' endometrial carcinomas.
León-Castillo A; Gilvazquez E; Nout R; Smit VT; McAlpine JN; McConechy M; Kommoss S; Brucker SY; Carlson JW; Epstein E; Rau TT; Soslow RA; Ganesan R; Matias-Guiu X; Oliva E; Harrison BT; Church DN; Gilks CB; Bosse T
J Pathol; 2020 Mar; 250(3):312-322. PubMed ID: 31829447
[TBL] [Abstract][Full Text] [Related]
25. Microcystic elongated and fragmented (MELF) pattern of invasion: Molecular features and prognostic significance in the PORTEC-1 and -2 trials.
van den Heerik ASVM; Aiyer KTS; Stelloo E; Jürgenliemk-Schulz IM; Lutgens LCHW; Jobsen JJ; Mens JWM; van der Steen-Banasik EM; Creutzberg CL; Smit VTHBM; Horeweg N; Bosse T
Gynecol Oncol; 2022 Sep; 166(3):530-537. PubMed ID: 35840357
[TBL] [Abstract][Full Text] [Related]
26. Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma.
Huvila J; Talve L; Carpén O; Edqvist PH; Pontén F; Grénman S; Auranen A
Gynecol Oncol; 2013 Sep; 130(3):463-9. PubMed ID: 23777659
[TBL] [Abstract][Full Text] [Related]
27. Variability in endometrial carcinoma pathology practice: opportunities for improvement with molecular classification.
Thompson EF; Huvila J; Jamieson A; Leung S; Lum A; Offman S; Lytwyn A; Sur ML; Hoang L; Irving J; van der Westhuizen N; Morin C; Bicamumpaka C; Azordegan N; Gougeon F; Ennour-Idrissi K; Senz J; McConechy MK; Aguirre-Hernandez R; Lui V; Kuo C; Bell C; Salisbury T; Lawson J; He E; Wang S; Chiu D; Kean S; Samouëlian V; Salvador S; Gotlieb W; Helpman L; Scott S; Wohlmuth C; Vicus D; Plante M; Talhouk A; Huntsman D; Parra-Herran C; Kinloch M; Grondin K; Gilks CB; McAlpine JN;
Mod Pathol; 2022 Dec; 35(12):1974-1982. PubMed ID: 36241860
[TBL] [Abstract][Full Text] [Related]
28. TCGA Molecular Prognostic Groups of Endometrial Carcinoma: Current Knowledge and Future Perspectives.
Arciuolo D; Travaglino A; Raffone A; Raimondo D; Santoro A; Russo D; Varricchio S; Casadio P; Inzani F; Seracchioli R; Mollo A; Mascolo M; Zannoni GF
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36232987
[TBL] [Abstract][Full Text] [Related]
29. TCGA molecular classification in endometriosis-associated ovarian carcinomas: Novel data on clear cell carcinoma.
Similä-Maarala J; Soovares P; Pasanen A; Ahvenainen T; Vahteristo P; Bützow R; Lassus H
Gynecol Oncol; 2022 Jun; 165(3):577-584. PubMed ID: 35370008
[TBL] [Abstract][Full Text] [Related]
30. The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study.
van Weelden WJ; Reijnen C; Küsters-Vandevelde HVN; Bulten J; Bult P; Leung S; Visser NCM; Santacana M; Bronsert P; Hirschfeld M; Colas E; Gil-Moreno A; Reques A; Mancebo G; Huvila J; Koskas M; Weinberger V; Bednarikova M; Hausnerova J; Snijders MPLM; Matias-Guiu X; Amant F;
Hum Pathol; 2021 Mar; 109():80-91. PubMed ID: 33338506
[TBL] [Abstract][Full Text] [Related]
31. Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts.
Stelloo E; Nout RA; Osse EM; Jürgenliemk-Schulz IJ; Jobsen JJ; Lutgens LC; van der Steen-Banasik EM; Nijman HW; Putter H; Bosse T; Creutzberg CL; Smit VT
Clin Cancer Res; 2016 Aug; 22(16):4215-24. PubMed ID: 27006490
[TBL] [Abstract][Full Text] [Related]
32. The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas.
Heinze K; Cairns ES; Thornton S; Harris B; Milne K; Grube M; Meyer C; Karnezis AN; Fereday S; Garsed DW; Leung SCY; Chiu DS; Moubarak M; Harter P; Heitz F; McAlpine JN; DeFazio A; Bowtell DDL; Goode EL; Pike M; Ramus SJ; Pearce CL; Staebler A; Köbel M; Kommoss S; Talhouk A; Nelson BH; Anglesio MS
Clin Cancer Res; 2023 Sep; 29(17):3471-3483. PubMed ID: 37339172
[TBL] [Abstract][Full Text] [Related]
33. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset.
Garg K; Shih K; Barakat R; Zhou Q; Iasonos A; Soslow RA
Am J Surg Pathol; 2009 Dec; 33(12):1869-77. PubMed ID: 19898223
[TBL] [Abstract][Full Text] [Related]
34. Incorporation of molecular characteristics into endometrial cancer management.
Vermij L; Smit V; Nout R; Bosse T
Histopathology; 2020 Jan; 76(1):52-63. PubMed ID: 31846532
[TBL] [Abstract][Full Text] [Related]
35.
De Leo A; de Biase D; Lenzi J; Barbero G; Turchetti D; Grillini M; Ravegnini G; Angelini S; Zamagni C; Coluccelli S; Dondi G; De Iaco P; Perrone AM; Tallini G; Santini D; Ceccarelli C
Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33668727
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of lymphovascular space invasion according to the molecular subgroups in endometrial cancer.
Siegenthaler F; Epstein E; Büchi CA; Gmür A; Saner FACM; Rau TT; Carlson JW; Mueller MD; Imboden S
Int J Gynecol Cancer; 2023 Nov; 33(11):1702-1707. PubMed ID: 37666529
[TBL] [Abstract][Full Text] [Related]
37. Distribution of estrogen and progesterone receptors isoforms in endometrial cancer.
Kreizman-Shefer H; Pricop J; Goldman S; Elmalah I; Shalev E
Diagn Pathol; 2014 Mar; 9():77. PubMed ID: 24684970
[TBL] [Abstract][Full Text] [Related]
38. Corded and hyalinized endometrioid carcinoma: Summary of clinical, histological, immunohistochemical and molecular data.
Travaglino A; Arciuolo D; Santoro A; Raffone A; Raimondo D; Casadio P; Seracchioli R; Fulgione C; Guida M; Mollo A; Inzani F; Zannoni GF
Pathol Res Pract; 2023 Jul; 247():154515. PubMed ID: 37209572
[TBL] [Abstract][Full Text] [Related]
39. Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment.
Leon-Castillo A; Horeweg N; Peters EEM; Rutten T; Ter Haar N; Smit VTHBM; Kroon CD; Boennelycke M; Hogdall E; Hogdall C; Nout RRA; Creutzberg CL; Ortoft G; Bosse T
Gynecol Oncol; 2022 Mar; 164(3):577-586. PubMed ID: 35078648
[TBL] [Abstract][Full Text] [Related]
40. Androgen Receptor Expression in Endometrial Carcinoma.
Zadeh SL; Duska LR; Mills AM
Int J Gynecol Pathol; 2018 Mar; 37(2):167-173. PubMed ID: 28582344
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
